000144856 001__ 144856
000144856 005__ 20240229112640.0
000144856 0247_ $$2doi$$a10.1038/s41419-019-1926-1
000144856 0247_ $$2pmid$$apmid:31541075
000144856 037__ $$aDKFZ-2019-02280
000144856 041__ $$aeng
000144856 082__ $$a570
000144856 1001_ $$aSenfter, Daniel$$b0
000144856 245__ $$aHigh impact of miRNA-4521 on FOXM1 expression in medulloblastoma.
000144856 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2019
000144856 3367_ $$2DRIVER$$aarticle
000144856 3367_ $$2DataCite$$aOutput Types/Journal article
000144856 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577104682_18928
000144856 3367_ $$2BibTeX$$aARTICLE
000144856 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144856 3367_ $$00$$2EndNote$$aJournal Article
000144856 520__ $$aMedulloblastoma, an embryonal tumor of the cerebellum/fourth ventricle, is one of the most frequent malignant brain tumors in children. Although genetic variants are increasingly used in treatment stratification, survival of high-risk patients, characterized by leptomeningeal dissemination, TP53 mutation or MYC amplification, is still poor. FOXM1, a proliferation-specific oncogenic transcription factor, is deregulated in various solid tumors, including medulloblastoma, and triggers cellular proliferation, migration and genomic instability. In tissue samples obtained from medulloblastoma patients, the significant upregulation of FOXM1 was associated with a loss of its putative regulating microRNA, miR-4521. To understand the underlying mechanism, we investigated the effect of miR-4521 on the expression of the transcription factor FOXM1 in medulloblastoma cell lines. Transfection of this microRNA reduced proliferation and invasion of several medulloblastoma cell lines and induced programmed cell death through activation of caspase 3/7. Further, downstream targets of FOXM1 such as PLK1 and cyclin B1 were significantly reduced thus affecting the cell cycle progression in medulloblastoma cell lines. In conclusion, a restoration of miRNA-4521 may selectively suppress the pathophysiological effect of aberrant FOXM1 expression and serve as a targeted approach for medulloblastoma therapy.
000144856 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144856 588__ $$aDataset connected to CrossRef, PubMed,
000144856 7001_ $$aSamadaei, Mahzeiar$$b1
000144856 7001_ $$00000-0003-3017-8240$$aMader, Robert M$$b2
000144856 7001_ $$aGojo, Johannes$$b3
000144856 7001_ $$aPeyrl, Andreas$$b4
000144856 7001_ $$aKrupitza, Georg$$b5
000144856 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b6$$udkfz
000144856 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b7$$udkfz
000144856 7001_ $$aHaberler, Christine$$b8
000144856 7001_ $$00000-0003-0388-7965$$aRicken, Gerda$$b9
000144856 7001_ $$aCzech, Thomas$$b10
000144856 7001_ $$aSlavc, Irene$$b11
000144856 7001_ $$aMadlener, Sibylle$$b12
000144856 773__ $$0PERI:(DE-600)2541626-1$$a10.1038/s41419-019-1926-1$$gVol. 10, no. 10, p. 696$$n10$$p696$$tCell death & disease$$v10$$x2041-4889$$y2019
000144856 909CO $$ooai:inrepo02.dkfz.de:144856$$pVDB
000144856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000144856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000144856 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144856 9141_ $$y2019
000144856 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL DEATH DIS : 2017
000144856 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144856 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144856 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144856 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144856 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000144856 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000144856 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000144856 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000144856 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144856 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144856 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144856 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144856 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144856 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELL DEATH DIS : 2017
000144856 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000144856 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000144856 980__ $$ajournal
000144856 980__ $$aVDB
000144856 980__ $$aI:(DE-He78)B062-20160331
000144856 980__ $$aI:(DE-He78)L101-20160331
000144856 980__ $$aUNRESTRICTED